Eden Biodesign and UMIP develop innovative cancer treatment

UK company Eden Biodesign, a specialist provider of development and manufacturing services for new biopharmaceutical medicines, has been selected by The University of Manchester Intellectual Property Limited (UMIP) to provide a range of services for the development of a novel therapeutic for treatment of macular degeneration and cancer.

UMIP is the university's managing agent for intellectual property commercialisation and works in positive relationships with researchers, entrepreneurs, business people, professional advisers and investors.

"The experience of Eden Biodesign's management team in the development of biologics ensures that our programme will be well positioned for an accelerated clinical development and will increase the value of our programme to industrial partners," said Professor Paul Bishop, School of Medicine, University of Manchester, who leads the team that discovered the new therapeutic.

Professor Bishop has been awarded a grant from the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA) towards the cost of the project. The project will be executed at the state-of-the-art NBC, operated by Eden Biodesign and funded by NWDA, European Regional Development Fund (ERDF) and Department of Trade and Industry (DTI).

"We look forward to helping UMIP and Professor Bishop to accelerate the transfer of this new therapy from research labs into clinical development," said Dr Crawford Brown, ceo of Eden Biodesign. 'Eden Biodesign has the expertise in product development and manufacturing that is critical to ensure clinical and commercial success of this product."